David Nierengarten analyst WEDBUSH

Currently out of the existing stock ratings of David Nierengarten, 245 are a BUY (81.13%), 56 are a HOLD (18.54%), 1 are a SELL (0.33%).

David Nierengarten

Work Performance Price Targets & Ratings Chart

Analyst David Nierengarten, employed at WEDBUSH, carries an average stock price target met ratio of 43.36% that have a potential upside of 43.92% achieved within 208 days on average.

David Nierengarten’s has documented 690 price targets and ratings displayed on 59 stocks. The coverage is on Healthcare, Communication Services, Technology sectors.

Most recent stock forecast was given on KPTI, Karyopharm Therapeutics at 03-Jun-2024.

Wall Street Analyst David Nierengarten

Analyst best performing recommendations are on SRRK (SCHOLAR ROCK HOLDING CORP).
The best stock recommendation documented was for SRRK (SCHOLAR ROCK HOLDING CORP) at 6/18/2018. The price target of $25 was fulfilled within 1 day with a profit of $3.57 (16.66%) receiving and performance score of 166.59.

Average potential price target upside

ANAB AnaptysBio ARAV Aravive ARGX argenx NV ADR AVRO AVROBIO BEAM Beam Therapeutics  BLUE Bluebird bio BPMC Blueprint Medicines Corp CDAK Codiak BioSciences  COGT Cogent Biosciences EPZM Epizyme FATE Fate Therapeutics GTHX G1 Therapeutics INZY Inozyme Pharma  ITOS Iteos Therapeutics  KPTI Karyopharm Therapeutics MGNX MacroGenics MYOK MyoKardia NTLA Intellia Therapeutics NUVB Nuvation Bio NVCR Novocure Ltd ORTX Orchard Therapeutics PLC STML Stemline Therapeutics STRO Sutro Biopharma TC TuanChe ADR TCRR Tcr2 Therapeutics TPTX Turning Point Therapeutics TSVT 2Seventy Bio XNCR Xencor YMAB Y mAbs Therapeutics CDTX Cidara Therapeutics KNSA Kiniksa Pharmaceuticals Ltd SRRK Scholar Rock Holding Corp SWTX SpringWorks Therapeutics VYGR Voyager Therapeutics AGTC Applied Genetic ARDX Ardelyx MRUS Merus BV PRTA Prothena plc RARE Ultragenyx KNTE Kinnate Biopharma  VOR Vor Biopharma BMRN Biomarin Pharmaceutical MGTA Magenta Therapeutics NFLX Netflix BOLD Audentes Therapeutics FENC Fennec Pharmaceuticals ISEE IVERIC bio NUVL Nuvalent ONCE Spark Therapeutics THRX Theseus Pharmaceuticals CMRX Chimerix MRSN Mersana Therapeutics FRLN Freeline Therapeutics Holdings Plc GBIO Generation Bio Co FUSN Fusion Pharmaceuticals  MAXN Maxeon Solar Technologies Ltd ORIC Oric Pharmaceuticals  IMNM Immunome  TCRX Tscan Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

34

$11.11 (48.54%)

20

1 months 11 days ago

9/16 (56.25%)

$10.59 (45.24%)

78

Hold

28

$5.11 (22.32%)

31

2 months 20 days ago

2/8 (25%)

$6.68 (31.33%)

459

Buy

50

$27.11 (118.44%)

130

4 months ago

0/2 (0%)

$24.51 (96.16%)

Buy

44

$21.11 (92.22%)

45

7 months 18 days ago

2/7 (28.57%)

$26.47 (151.00%)

229

Hold

21

$-1.89 (-8.26%)

29

7 months 20 days ago

4/9 (44.44%)

$4.46 (26.96%)

125

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is David Nierengarten is most bullish on?

Potential upside of $133.13 has been obtained for ARGX (ARGENX NV ADR)

Which stock is David Nierengarten is most reserved on?

Potential downside of -$8.55 has been obtained for FUSN (FUSION PHARMACEUTICALS )

What Year was the first public recommendation made by David Nierengarten?

On 2011

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?